 The FDA declined Humanigen Incs NASDAQ: HGEN request for emergency use authorization EUA of its lenzilumab drug to treat newly hospitalized COVID-19 patients. The Company filed its application with the FDA for emergency drug use in May, citing late-stage trial data. 